In an exploratory phase 2 trial in patients having ovarian cancer surgery, the anti-FXI antibody SHR-2004 vs enoxaparin-rivaroxaban: 28-day VTE in 12.6% vs 20.2% of 181 analysed (difference −8.4%, 95% CI −19.9 to 3.1; not significant). Major/CRNM bleeding 2.2% vs 1.9%.
RCTn = 198
Jiang et al. SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study